Why 2025–2026 feels like a turning point for India CBD FSSAI 2025 compliance
India’s food regulators are signaling a long-needed modernization of license renewal cycles under the Food Safety and Standards Authority of India (FSSAI). In parallel, brands exploring CBD-based ingestibles continue to face a far more complex reality: product classification is fragmented, ingredient permissions are narrow, and enforcement risk remains highly sensitive due to India’s narcotics framework.
This article is informational (not legal advice). It maps the practical split between:
- when a product is likely to sit in the FSSAI “food” regime
- when it is pushed toward the Ministry of AYUSH pathway (ASU drugs)
- where imports and e‑commerce controls commonly fail in audits
It also provides a compliance calendar so teams can tie FSSAI renewal changes to real SOP updates.
External references throughout link to primary regulators and statutes, including FSSAI’s portal at https://www.fssai.gov.in/ and AYUSH at https://ayush.gov.in/.
The regulatory baseline: India’s “food” law vs. “ASU drug” law vs. NDPS sensitivities
FSSAI: licensing is straightforward—ingredient permission is not
FSSAI’s licensing framework (via the Licensing & Registration of Food Businesses Regulations) is relatively well-defined for ordinary foods and supplements. Food businesses typically select a validity term (commonly 1–5 years), renew before expiry, and maintain hygiene, labeling, and traceability controls.
Where CBD brands struggle is not the license itself; it’s the question: is CBD permitted as a food ingredient? Under India’s food system, ingredients for supplements/functional foods must be permitted under applicable regulations and schedules, or obtain approval as novel food (where applicable).
Useful starting points:
AYUSH: a structured route when positioned as traditional systems medicine
The Ministry of AYUSH oversees Ayurveda, Yoga & Naturopathy, Unani, Siddha, and Homoeopathy. Products framed as ASU drugs (with permitted ingredients, permitted plant parts, appropriate therapeutic positioning, and compliant manufacturing licensing) often route through state-level AYUSH licensing authorities and the Drugs & Cosmetics framework.
Key references:
NDPS Act: the enforcement backdrop you cannot ignore
Even if a brand thinks it has a “wellness” product, the legal sensitivity arises from India’s narcotics law—particularly the Narcotic Drugs and Psychotropic Substances Act, 1985 (NDPS). Enforcement agencies may scrutinize extracts, resins, and parts of the plant that the NDPS definition treats as narcotic, and may test products where the source material, extraction method, or THC presence is unclear.
Primary law reference:
FSSAI’s September 2025 renewal overhaul: what it’s trying to fix
Food operators have long complained that license renewals can become a compliance “cliff”: differing validity choices across sites, missed renewal windows, and inconsistent renewals that make internal audits messy.
In September 2025, FSSAI signaled proposals aimed at rationalizing renewal cycles and extending/standardizing validity to reduce churn and make compliance more predictable for operators. Even if your CBD ingestible strategy remains constrained, these renewal changes matter because many CBD-adjacent operators still hold food licenses for:
- hemp seed foods (where permitted)
- beverages and snacks that avoid cannabinoids
- “wellness” products that are food-category but not cannabinoid-based
What businesses should do now (even before finalization)
Because proposals can evolve before implementation, treat 2025–2026 as a readiness period:
- Inventory every FSSAI license/registration across entities, warehouses, and brands.
- Align validity end-dates and internal renewal reminders.
- Update vendor onboarding to confirm suppliers’ FSSAI license status and validity windows.
- Build a renewal evidence pack (Form, fee receipt, inspection notes, corrective action closure) for each site.
Internal link: For ongoing tracking of multi-jurisdiction compliance tasks, see https://cannabisregulations.ai/.
Food vs. AYUSH: a practical classification map for CBD brands
The biggest compliance error in India is treating “CBD” as a single category. Regulators and enforcement bodies tend to look at:
- source material (seed, leaf, flower, resin)
- extraction method and “full spectrum” vs isolate claims
- THC presence (and whether you can prove it consistently)
- intended use (food vs therapeutic)
- claims (general wellness vs disease treatment)
Below is a practical map for risk-triage.
When a product is most likely in FSSAI’s food regime
A product is more plausibly “food” when it:
- uses permitted food ingredients (commonly seed-based ingredients) rather than cannabinoid extracts
- avoids therapeutic/disease claims
- fits within an existing food category with compliant labeling (nutrition facts, ingredients, allergen statements)
Caution: Even within food, “CBD” as an added functional ingredient can trigger novel food questions and potential non-compliance if the ingredient is not clearly permitted. Teams should conduct a formal ingredient-permission review against FSSAI’s applicable regulations (including supplements/nutraceutical frameworks).
When the product trends toward AYUSH (ASU drug pathway)
A product trends toward AYUSH when:
- it is positioned as an Ayurvedic/Unani/Siddha formulation
- it uses ingredients/plant parts that are acceptable under the relevant pharmacopeial or classical references
- it is manufactured under an appropriate ASU manufacturing license and GMP expectations
- labeling and advertising align with ASU drug norms and avoid prohibited “magic cure” type promotion
Key risk point: positioning a CBD oil/tincture as a medicine can invite a higher bar for manufacturing controls and claims substantiation—and can still face NDPS scrutiny if the extract source or THC handling is unclear.
Red flags that can push products into enforcement action
Regardless of whether you “picked” FSSAI or AYUSH, these are common enforcement triggers:
- “Full spectrum” or “flower extract” language without a defensible legal basis
- inconsistent THC test results batch-to-batch
- importing bulk extracts without clean paperwork and classification clarity
- disease claims (anxiety, cancer, epilepsy, chronic pain) on labels or marketplaces
- influencer marketing that implies treatment
Labeling and claims guardrails (food and AYUSH)
Food labeling guardrails (FSSAI expectations)
For food-category goods, expect scrutiny on:
- identity of the product (what it is, not what it promises)
- complete ingredient list and additives
- nutrition information where required
- manufacturer/packer/importer details and FSSAI license number
- batch/lot, dates, veg/non-veg mark (where applicable)
Claims: keep to conservative, non-therapeutic language. “Supports calm” can still be sensitive; “treats anxiety” is a much higher-risk claim.
References:
AYUSH labeling and advertising guardrails
For ASU drugs, the label and promotional posture must align with AYUSH/drug rules and India’s restrictions on objectionable advertisements.
Practical controls:
- ensure product category is clearly identified as ASU drug where applicable
- avoid “guaranteed cure” statements
- build a claim-review workflow that includes the Drugs and Magic Remedies (Objectionable Advertisements) Act sensitivity
Primary law reference:
Imports: documentation and border-control realities
Importing CBD-adjacent goods into India is often where compliance strategies collapse. Importers may face:
- customs classification disputes
- requests for additional lab reports
- re-labeling or sampling at port
- rejection or detention if documents conflict with the nature of the goods
If you import food products (FSSAI route)
Food imports typically run through FSSAI’s Food Import Clearance System (FICS) with inspection/sampling at ports.
Operational checklist (common expectations):
- importer’s FSSAI license/registration
- product label compliance (or sticker labeling plan, where permissible)
- COA from accredited labs for key parameters
- product specification sheet and ingredient declarations
- traceability documents (invoice, packing list, bill of lading, country of origin)
Reference:
If you import AYUSH-category products
For AYUSH drugs, importers should plan for:
- confirmation that the product is an ASU drug (not a food)
- manufacturing licensing documentation from origin country
- India-side AYUSH licensing and any required registrations
- scrutiny of ingredients/plant parts and extract type
Because practices can differ by port and by officer, brands should maintain a conservative documentation posture and pre-align classification arguments.
State-level enforcement hotspots and why they matter for SOPs
India’s enforcement risk is not uniform. Local police, excise/narcotics units, and food/drug authorities can interpret the same product differently, especially when “CBD” appears in marketing.
While enforcement patterns change over time, brands often report higher scrutiny in large consumption and logistics hubs—major metros, airport-linked import channels, and states with active anti-narcotics actions.
SOP implication: build a state-by-state distribution risk register:
- warehouse locations and last-mile partners
- local counsel escalation contacts
- product list allowed per state channel (e.g., food-only SKUs in higher-scrutiny regions)
- incident response playbook (sample seizure, notice response timelines, recall triggers)
E‑commerce checklist for CBD-adjacent products in India
E-commerce is where labels, claims, and KYC fail visibly. Even for non-ingestible wellness products, marketplaces and regulators expect robust consumer protection controls.
Primary reference:
Marketplace policy alignment (before you list)
- Obtain and archive the marketplace’s category policy for supplements/health products.
- Confirm whether the marketplace bans “CBD” keywords outright, even if products are lawful.
- Maintain a list of “blocked terms” for titles, bullets, and ad copy.
Seller KYC and traceability
For brands operating as sellers (or enabling third-party sellers):
- maintain KYC and entity verification documents
- maintain invoices and batch-level traceability for every unit sold
- keep manufacturer/packer/importer declarations aligned across label, listing, and invoice
Age gates and sensitive-product UX
Even without explicit adult-only classification, implement conservative controls:
- age affirmation at checkout for sensitive wellness categories
- no youth-oriented creatives
- restrict ads to compliant audiences where the platform supports it
Returns handling and quarantine SOP
Returns are a hidden compliance minefield.
- treat returned ingestibles as non-resalable unless your QA system supports sealed-condition verification
- quarantine returns, record lot numbers, and tie back to complaints
- define destruction and documentation procedures
Customer support and grievance workflow
Under e-commerce consumer protection expectations:
- publish a grievance contact and resolution timeline
- log adverse event complaints and quality complaints separately
- create an escalation lane for “regulatory notice received” events
Packaged commodity declarations (online and on pack)
Ensure the product page and packaging align with packaged commodity and labeling expectations:
- MRP, net quantity, importer/manufacturer details
- consumer care contact
- batch/lot and dates
Reference for legal metrology framework:
Compliance calendar: tying FSSAI renewal changes to CBD brand SOP updates
Below is a practical calendar you can implement even while FSSAI’s 2025 proposal moves toward final form.
Month 0–1: governance and classification
- appoint a single internal owner for India CBD FSSAI 2025 compliance
- build a SKU classification memo: food vs ASU drug vs non-ingestible
- freeze high-risk claims and rewrite product pages
Month 2–3: licensing, vendor controls, and testing
- map all FSSAI/AYUSH licenses by site and entity
- adopt a batch testing plan (THC presence where relevant; contaminants; stability)
- onboard labs and define COA acceptance criteria
Month 4–6: import readiness and e‑commerce hardening
- create an import dossier template (COA, specs, labels, invoices)
- configure marketplace listing compliance and blocked-terms list
- implement returns quarantine and destruction SOP
Month 7–9: renewal cycle alignment and audit simulation
- align license validity choices to reduce staggered expiries (where permitted)
- run a mock inspection audit: labels, warehouse hygiene, traceability, complaint logs
- train customer support on claim boundaries and escalation procedures
Month 10–12: continuous compliance
- schedule quarterly listing reviews (claims drift is common)
- conduct supplier re-verification and COA trend review
- refresh state-level risk register and logistics routes
Key takeaways for operators and investors
- FSSAI renewal modernization is positive for food operators, but it does not automatically open the door to CBD ingestibles.
- The biggest India risk is misclassification: treating a high-sensitivity extract product like an ordinary supplement.
- Labeling and claims discipline is not “marketing hygiene”—it is a regulatory control.
- Imports and e-commerce require documentary rigor and conservative UX policies.
Next steps
If your team is building a lawful India footprint, treat compliance as a product feature: classification memos, claim review, batch testing, import dossiers, and renewal calendars should be standardized across every SKU and channel.
For ongoing monitoring and workflow support, use https://cannabisregulations.ai/ to centralize licensing, policy updates, and operational compliance checklists.
